Prior Authorization Required

Prior authorization is required for phototherapy services and for home phototherapy equipment (UVB panels/booths and replacement bulbs) when covered. Document the diagnosis, prior therapies tried, and clinical rationale that conventional therapies failed or were inappropriate. For home UVB DME, include a prescription specifying device model, treatment area, and medical necessity (e.g., severe psoriasis with frequent flares and inability to attend on-site therapy; atopic dermatitis unable to attend on-site therapy).

• Prior authorization required for selected CPT/HCPCS when selection criteria are met
• Home UVB devices (E0691–E0694; A4633) covered only if criteria met and PA obtained

Authorization Requirements for PUVA

PUVA (psoralens + UVA) has specific authorization requirements: confirm that conventional (topical/systemic) therapies have failed or are unsuitable, and that no absolute contraindications to PUVA are present. Document that benefits are expected to outweigh risks for the requested indication and setting (office-administered is preferred for safety).

• PUVA generally considered medically necessary only after conventional therapies have failed
• Home PUVA is considered investigational/unsupported and is not covered

Document Topical Preparations and Skin Protection

Document all concomitant topical preparations and skin protection measures. Note use of emollients (e.g., petrolatum) or other agents applied before phototherapy, and whether sunscreens or salicylic acid preparations that may block UV penetration are avoided on treatment areas. Describe any intentional UV-blocking applied to uninvolved skin.

• List topical agents applied prior to each treatment (emollients, keratolytics, sunscreens)
• Indicate sites protected with physical/or topical UV blockers (e.g., zinc oxide)

Prior Therapy and Symptom Metrics

For indications with symptom-driven endpoints (e.g., mastocytosis/indolent systemic mastocytosis with pruritus), document prior therapies tried, objective and patient-reported symptom metrics (e.g., pruritus VAS), number of prior treatment failures, and reason for escalation to phototherapy.

• Record prior antihistamine trials and other systemic/topical agents for mastocytosis
• Provide pruritus severity using VAS or similar and document baseline and prior responses

Indications, Contraindications, and Treatment Setting

Authorization must explicitly state the indication, relevant contraindications have been assessed and excluded, and the treatment setting (office vs home). For example, confirm indication such as early-stage mycosis fungoides, severe refractory atopic dermatitis, or refractory mastocytosis, and that home therapy is requested only for allowed diagnoses (severe psoriasis, selected atopic dermatitis).

• Confirm indication (e.g., early-stage mycosis fungoides vs extensive CTCL)
• State planned setting: office-based phototherapy preferred; home UVB only when criteria met

Denied Equipment / Approaches

Certain equipment and approaches are considered not medically necessary or not covered. Tanning beds for home phototherapy and home PUVA are not covered.

• Tanning beds for home UVB phototherapy — not medically necessary
• Home PUVA — insufficient evidence; not covered

Contraindications That May Trigger Denial

Several contraindications should trigger denial or require clear documentation that they are absent prior to authorization for PUVA or UV phototherapy. Explicitly document absence of history of arsenic exposure, prior ionizing radiation to the treatment site, history or presence of melanoma or other skin cancer, pregnancy, photosensitivity disorders, and relevant photosensitizing medications.

• History of arsenic exposure — contraindication
• History of ionizing radiation exposure or radiodermatitis — contraindication
• History or presence of melanoma or nonmelanoma skin cancer — contraindication
• Pregnancy — contraindication
• Photosensitivity disorders (e.g., xeroderma pigmentosum, porphyria) — contraindication
• Concomitant photosensitizing drugs or significant hepatic impairment should be documented

Histological Confirmation Important to Avoid Misdiagnosis

For conditions where radiation-induced morphea (RIM) is in the differential, histological confirmation is crucial. Failure to obtain or document biopsy/histology distinguishing RIM from recurrence, chronic radiation dermatitis, or other mimics may lead to misdiagnosis and impact coverage decisions.

• Obtain histologic confirmation when radiation-induced morphea is suspected
• Document multidisciplinary evaluation when diagnosis is uncertain

Weak Evidence May Risk Denial

Weak or low-quality evidence for some indications may increase risk of denial. Provide strong clinical rationale, citation of guideline recommendations, or higher-quality supporting literature when requesting phototherapy for less well-established indications.

• Indications supported only by case series or single reports require supportive literature or guideline backing
• Document why alternative treatments are unsuitable or have failed

Contraindications That May Preclude Coverage

Certain absolute or relative contraindications may preclude coverage. If present, document clinical rationale for any exception and consult medical policy medical director if applicable.

• Absolute contraindications (e.g., xeroderma pigmentosum, lupus erythematosus) — generally preclude therapy
• Relative contraindications (e.g., prior arsenic or ionizing radiation, transplant immunosuppression) — may preclude coverage depending on risk assessment

Evidence Insufficiency Risk

Insufficient or low-quality evidence (single-case reports, small uncontrolled series) used as the sole justification for coverage may lead to denial. When evidence is limited, include clinical course, objective measures, and prior treatment failures to strengthen the request.

• Cite higher-quality studies or guideline recommendations when available
• Provide objective outcome measures (e.g., VAS scores, cumulative exposures) if relying on limited evidence

Monitoring and Device Documentation

Monitoring requirements and device documentation: for home phototherapy patients, document a dermatology follow-up and regular skin examinations. For DME home UVB devices, include prescription details, device specifications, training provided, and a monitoring plan (frequency of follow-up visits, skin checks). Replacement bulbs may require prescription and PA documentation.

• Regular dermatologic skin exams required for home phototherapy patients
• Device prescription should include model, panel size, intended treatment area, and recommended dosing schedule
• Replacement bulbs (A4633) require documentation of medical necessity and prescription

Monitoring and Patient Education

Patient education and oversight: document that patients receiving home phototherapy were instructed on device use, eye protection, identification of suspicious lesions, avoidance of tanning salons, and the need to stop therapy and seek evaluation if new or changing lesions appear.

• Provide written patient education on device operation and safety
• Document training on eye protection, dosing, and signs of skin cancer or severe reactions
• Advise against use of tanning salons and unsupervised PUVA

Suggested Clinical Documentation Elements

Suggested clinical documentation elements to include in authorization requests: baseline disease severity/extent, number of prior exposures/treatments, cumulative UV dose if previously treated, pruritus or symptom VAS scores, serum markers if relevant (e.g., tryptase in mastocytosis), and histology reports when applicable.

• Number of prior phototherapy exposures and cumulative J/cm2 when available
• Baseline and serial pruritus VAS or other symptom scales
• Relevant labs (e.g., serum tryptase) and histology or biopsy reports

Required Clinical Documentation

Required clinical documentation for authorization: primary diagnosis (ICD-10), prior therapies and duration, reason for discontinuation or failure, extent of disease (BSA% or descriptive), planned phototherapy modality and regimen, contraindications assessed and ruled out, and supporting literature or guideline citations when applicable.

• Primary ICD-10 diagnosis and clinical staging where applicable (e.g., early-stage MF)
• Detail prior topical/systemic therapies, durations, and responses
• Planned treatment frequency, duration, and setting (office vs home)

Supportive Clinical References

When clinical evidence is mixed, include supportive clinical references or guideline preference to justify modality choice (e.g., NB-UVB often preferred over PUVA for safety and ease of administration; cite AAD, UpToDate, or consensus guidelines for MF, mastocytosis, pityriasis lichenoides).

• Cite guideline recommendations (AAD, U.S. Cutaneous Lymphoma Consortium) when available
• If selecting PUVA over NB-UVB, document rationale and supporting evidence

Therapy Sequencing Considerations

Therapy sequencing considerations: phototherapy is typically positioned after failure of first-line topical and/or systemic therapies. For certain conditions there are preferred sequences (e.g., topical corticosteroids before PUVA/NB-UVB; NB-UVB often preferred as first-line phototherapy due to safety profile). Document prior steps and rationale for sequencing chosen.

• Document that topical corticosteroids or other first-line treatments were attempted when standard of care
• If requesting PUVA as second-line, explain why NB-UVB was not appropriate or available

Suggested Treatment Sequencing

Suggested treatment sequencing examples: NB-UVB is often first-line for pityriasis lichenoides and many non-psoriatic conditions; methotrexate or oral erythromycin may be used as second-line where indicated. For localized scleroderma (morphea), systemic corticosteroids plus methotrexate are often first-line for progressive disease; phototherapy is appropriate for superficial circumscribed subtypes or adolescents.

• NB-UVB preferred for pityriasis lichenoides; consider oral erythromycin or methotrexate as alternatives
• For morphea: systemic steroids + methotrexate for progressive localized disease; phototherapy for superficial subtypes

Administrative Notes / None Specified

No additional provider actions specified in these source chunks beyond the above; administrative policy history and notices are present in the policy footer. Providers remain responsible for treatment decisions and should follow documentation and prior authorization processes.

• Clinical Policy Bulletins are administrative tools and do not replace clinical judgment
• Follow PA and documentation requirements outlined above